compani
trulic rewind would sustain posit inject
rais sales/ep vs street
track hit sale growth target expand
margin diabet franchis revenu project reach
compound-annual-growth-rate trulic posit benefit
market expans nvo ozemp launch cv data need
rewind taltz psa/olumi launch drive immunolog
innov asset sourc reiter
ep support dcf
diabet headwind manag rewind need
view provid conserv financi rang impli
sales/ep growth midpoint click initi thought
rais sale street
higher oncolog women neurosci
sale partial off-set lower diabet anim
revenu rais ep vs
street higher revenu lower tax remain track grow
revenu target expand margin key drive top line growth
diabet franchis project sale reach
compound-annual-growth-rate howev trulic face competit
novo nordisk nvo rate ozemp inject near-
term possibl oral sema long-term addit humalog
face biosimilar competit sanofi sni rate admelog
short act insulin analogu segment model assum trulic
account one-third global market
conting rewind cv outcom trial view basaglar
sale vs street off-set humalog leakag
growth de-risk addit indic expect meaning upward
pressur consensu estim model combin sale
taltz olumi vs street lli emerg pain franchis
galcanezumab/lasmiditan/ tanezumab repres anoth leg growth
sale approach oncolog look
sourc extern asset better posit must-win segment
model lli oncolog sale go
compound-annual-growth-rate sales/ep cagr vs
tr target
compani
street reiter buy pt ep support dcf
analysi risk thesi includ pricing/competit pressur especi diabet commerci
execut regulatori clinic ip alimta risk
trulic need deliv cv outcom rewind
lli diabet segment face competit headwind trulic jardianc basaglar growth
need off-set declin short act insulin product humalog/humulin model assum
doubl diabet busi level model
sale acknowledg commerci risk rise lli insulin busi
rise discount rebat sentiment echo novo nordisk call click
read-across note rapid-act insulin market sanofi biosimilar admelog launch
inject vial pen form us market gross wac price discount effect feb
humalog assum lli contract blunt impact admelog howev
model brand declin model humalog sale yoy vs street
pressur expect out-year model humalog sale
vs street model humulin sale yoy vs street
 vs street expect mitig risk short-act
insulin segment launch basaglar nvo sni report see price pressur
long-act insulin segment benefit pressur launch basaglar
model basaglar sale vs street posit side lli trulic
continu take share high-growth market model global
howev trulic face rise competit class nvo ozemp semaglutid
ozemp approv us decemb nvo start us commerci launch
feb assum ozemp approv eu japan nvo price ozemp
signific premium vs trulic like due brand enter
market posit cv outcom studi better glucos reduct weight loss see note
data nvo indic call payer access ozemp limit
approv came contract season like lead slow commerci uptak nvo
expect gener ozemp us sale usd vs street think impact
ozemp trulic modest howev note ozemp entri combin
victoza cv outcom benefit ad label august put pressur deliv
favor cv outcom benefit trulic rewind studi expect read-out
need posit cv benefit order trulic maintain leadership posit
out-year neg read-out rewind could materi hurt trulic growth prospect
out-year impact abil grow franchis materi under-penetrated market
base diabet market model expect lli trulic command one-third share
market market grow low-teen compound-annual-growth-rate model
trulic sale vs street
trulic could impact oral sema readout
previous outlin click note nvo invest substanti develop
oral formul semaglutid oral sema broad program includ phase
clinic trial pioneer trial expect data oral sema vs diet exercis
oral sema cv outcom trial vs placebo two
head-to-head trial vs asset vs jardianc
japanes patient vs trulic oral sema could disrupt product diabet
market view program consider clinic commerci risk despit
solid phase result publish jama peptid molecul like oral sema low bioavail
note scientif literatur could lead reduc efficaci vs inject
patient take oral sema may requir fast once-daili dose avoid
food-drug interact fast requir could confound clinic trial result physician
adher trial protocol although think unlik meaning factor given size
pioneer trial like view oral sema approv need fast
could decreas adher real world set concern low adher rate could potenti
make physician less like prescrib once-daili oral sema vs once-weekli inject
fast requir physician prescrib oral sema adher low could
lead patient attrit onto inject like trulic anoth treatment poor adher
lead lack real-world efficaci and/or safeti concern seen clinic set
page
compani
final lly/boehring ingelheim bi privat jardianc continu demonstr strong growth
new-to-brand nbrx prescript share exceed displac johnson johnson
rate invokana market leader black warn amput
risk ad invokana label may similar class believ jardianc
signific room grow due under-penetr oral diabet market
repres annual prescript written oral diabet drug estim
share shift older gener therapi jardianc equat sale conting
discount rebat put upward pressur out-year estim class take share
quickli anticip believ street appreci growth opportun
health failur chronic kidney diseas opportun expect heart failur trial
emperor-reduc emperor-preserv show rapid signific reduct
primari cv endpoint believ data may compel could lead stoppag
trial posit interim analysi aim initi jardianc chronic kidney diseas
trial collabor partner boehring ingelheim bi privat bullish
ckd indic base result empa-reg outcom studi jardianc show
reduct risk kidney diseas onset/progress click note model
jardianc allianc revenu vs street
olumi us launch taltz drive immunolog
re-fil olumi baricitinib jak inhibitor us treatment rheumatoid arthriti ra
decemb expect fda adcom meet focus addit data submit
april/may follow approv june note come acr click
overal incid deep vein thrombosi /or pulmonari embol dvt/pe olumi ra trial
measur per patient year well within background rate observ
ra patient saw incid dvt/pe phase atop dermat trial pursu
olumi atop dermat ad phase program initi jan psoriat arthriti
phase roll-out expect system lupu erythematosu sle evalu option
phase roll-out provid leg growth out-year note
call compani pleas olumi phase sle data
present major medic confer like eular june zurich switzerland
commerci olumi launch germani japan progress well report
sale qoq expect olumi see robust growth across multipl indic
next five year second jak-inhibitor enter immunolog market
hold xeljanz/xr report global sale year market
model olumi sale street model
olumi sale vs street
think taltz ixekizumab inhibitor pois growth beyond label expand
kicks-in psoriasi taltz gain share jnj inhibitor stelara ustekinumab
behind novarti nv rate inhibitor cosentyx secukinumab us market
cosentyx nbrx share ahead taltz click novarti read-
across posit side class whole see robust growth nbrx
share dermatolog impli taltz signific room left grow volum indic
taltz approv psoriat arthriti us dec click note
launch earli taltz also receiv approv europ late januari
expect commerci launch depend time price negoti read-out
lli three studi taltz ankylos spondyl coast-v coast-w coast-x expect
model taltz sale vs street model taltz sale
well street immunolog pipelin also inhibitor
mirikizumab mid-stag trial psoriasi pso crohn diseas cd think
robust efficaci gener like buy risankizumab valid
class plan initi phase trial mirikizumab pso cd
need extern asset improv oncolog posit
intrigu intern asset pipelin howev think oncolog area
need look bolster growth busi develop consid oncolog
must-win high growth area oncolog grow compound-annual-growth-rate
accord recent industri research need becom better posit order sustain
long-term franchis sale growth consist last earn call lli manag
page
compani
appear eager execut oncolog space lli ceo comment call
say look mani mani opportun would reason expect busi year
busi develop oncolog lilli remind click note enter
three small/early-stag deal oncolog bd expect aggress
pursu deal continu think lli bd-appetit strateg financi
standpoint focus early-stag asset support comment call
ambit phase phase concept earlier clinic asset main target
lilli rel underrepres lot go price point
think attract ideal think look tuck-in oncolog asset reason
valuat could potenti provid one commerci asset well sever intrigu
asset early-to-mid stage pipelin right asset becom avail think plenti
dri powder mid-siz acquisit cash short term secur
balanc sheet net debt/ebitda ratio think could pursu acquisit
larg without requir signific sharehold dilut assum like focus
primarili opportun rang
verzenio show earli success breast cancer market
posit side oncolog segment verzenio abemaciclib shown earli success
breast cancer market us nbrx share approach month launch
verzenio approv late septemb verzenio trx outperform nv
asset kisqali slow launch due safeti concern qt prolong hepatotox
issu narrow label lli result verzenio letrozol metastat
breast cancer click note show compar efficaci pfe ibranc view
remind fda accept verzenio snda base data prioriti review
octob expect approv pdufa date import note
verzenio current approv indic repres address market accord
lead us believ label expans would provid substanti boost
verzenio sale model verzenio sale vs street
cyramza face competit io agent esp japan
neg side cyramza struggl us face competit pressur
io agent expect see increas competit launch io asset ex-u market
especi japan near-term well neg outcom cyramza rainfal
studi first-lin gastric cancer posit benefit os benefit decid submit
data approv next catalyst overal surviv read-out rang studi evalu
cyramza chemo second-lin urotheli carcinoma bladder cancer expect
howev note five io agent alreadi approv
bladder cancer us mean commerci opportun cyramza may limit model
cyramza sale slightli street alimta pemetrex note
previous click think near-term risk true gener lift follow posit ptab
decis alimta vitamin patent patent octob howev
current defend patent court multipl nda filer look launch
altern salt formul pemetrex first case schedul begin southern
district court indiana februari case expect trial last less
week court render decis
lli balanc sheet enjoy next year
capit alloc strong balanc sheet busi project gener
next five year expect devot excess cash grow dividend
 share repurchas well small-to-mid size acquisit also think spin sale
busi would make strateg sens could provid compani
addit dri powder pursu accret particularli oncolog innov asset
often pricey final sustain innov launch key growth product
least one major market asset potenti label expans addit
think sever strong nme asset mid-to-l stage pipelin includ lasmiditan
pain mirikizumab immunolog diabet lanabecestat neurosci
underappreci investor
page
compani
anim could fetch sale/spin view
analysi strateg altern busi proceed
expect commun compani decis earn call juli mostli consist
previou time strateg think divest elanco busi make
strateg sens sharehold describ synergi anim
rather modest quantit expect eah remain drag lli overal revenu
growth human health compound-annual-growth-rate vs anim health margin ah
oper margin vs corpor averag financi despit modest
benefit us corpor tax reform still think click total consider
elanco busi like base combin dcf rel valu analysi base
estim impli ev ebitda would discount ev-weight peer
group averag although mostli in-lin industri leader zoeti rate
given elanco rocki perform revenu yoy yoy
below-averag margin think discount multipl justifi order sharehold receiv
full valu elanco regardless deal structur think need show two separ
relat posit develop first need show sale stabil particularli
anim busi yoy second need execut effici
cost-reduct goal quantifi impact chang investors/potenti bidder provid
convinc plan drive elanco margin expans toward profit peer
revenu growth lli presid mention call underestim
impact clean food movement competit howev point sever new
product help achiev flat slight increas overal anim health ah revenu growth
model yoy vs street despit continu pressur
anim busi market access issu posilac recombin bovin somatotropin rbst
competit pressur optaflexx ractopamin hydrochlorid sinc elanco launch
nine new product four companion anim five food anim yield sale
total ah revenu new launch particularli bullish gallipr first-in-
class anti-inflammatori canin osteo-arthr companion anim clynav first-in-class dna
vaccin salmon food anim recent name best product anim
pharm lead industri public gallipr also approv eu jan
expect launch overal expect low-to-mid singl digit declin food anim off-set
low-to-mid single-digit growth companion anim out-year hope
push overal elanco busi back toward mid-singl digit industri growth level model
ah flat margin expans elanco ebitda
margin current estim peer group averag ebitda
margin well expect get natur margin benefit
return revenu growth mix shift newer product across franchis well
overal slight mix shift toward companion anim addit elanco exit certain us distribut
agreement consolid manufactur facil larchwood ia anoth facil iowa
explor sale posilac franchis along manufactur facil augusta ga
drive margin expans overal think meet goal click
note drive elanco margin medium term expect elanco oper margin
reach
pain franchis provid anoth import leg growth
lli emerg pain franchis repres fourth leg growth diabet immunolog
oncolog expect regulatori decis lli cgrp galcanezumab galc chronic/
episod migrain cm/em fda accept bla decemb view galc
meaning launch opportun pain franchis state previous click
base cross-trial comparison view galc differenti competit class
base earlier onset effect durabl respons rate
 novarti pdufa cgrp asset aimovig erenumab may mean
approv aimovig like enter us market month ahead galc aim launch
galc auto-injector formul differenti galc aimovig base conveni
remind galc requir singl inject vs inject need aimovig administr
expect bulk galc use initi driven chronic migrain model galc sale
street teva rate fremanezumab
frema anoth key competitor fda action date june treatment cm/
page
compani
em frema expect distinct advantag quarterli dose per year vs monthli
dose per year competitor teva formul pre-filled syring vs amgn
pen formul teva announc call sole api manufactur celltrion
rate receiv fda warn letter manufactur facil
teva acquir prioriti review voucher appli frema bla applic jump ahead
competit howev believ manufactur issu like delay approval/
launch acut migrain set expect receptor agonist lasmiditan well-
posit take share approv click januari deep dive lasmiditan
collect long-term safeti data lasmiditan conduct drug-drug interact drive studi
file nda expect lasmiditan approv us
also develop anti-nerv growth factor monoclon antibodi tanezumab collabor
osteoarthr oa hip knee chronic low back pain read-out
first phase trial durat oa expect fall
remain phase trial oa phase week long-term safeti studi
chronic low back pain tango expect read first month
believ tanezumab significantli underappreci asset street offer pfe/
novel non-opioid entri global pain market share call
exclud nsaid concomit use tanezumab on-going phase oa trial avoid
previou safeti concern conting phase result expect lly/pf file tanezumab
global regulatori author
remind term lli agreement see state compani share
equal gross margin certain commerci expens tanezumab product
commerci lli specifi exact revenu recognit methodolog
assumpt would record net sale tanezumab pay allianc revenu net lli share
cog commerci expens cog line similar arrang
bi jardianc tradjenta think revenu opportun tanezumab
rel modest model peak risk-adjust sale howev jardianc
allianc revenu tanezumab book highli profit gross margin
lli neurosci asset carri high risk/reward
despit failur solanezumab click note novemb commit
neurosci franchis pursu monoclon antibodi target
treatment alzheim diseas ad conclud phase studi
activ bind amyloid- dose regimen appear safe despit modest immunogen
initi phase trial treatment earli symptomat ad patient
trial primari complet date march aim recruit patient
also believ may work combin bace inhibitor base intrigu
anim model click also pursu oral compound undisclos
mechan action treatment parkinson diseas dementia current
enrol patient phase trial presenc primari complet juli
also collabor astrazeneca azn rate develop two asset
lanabecestat bace inhibitor amyloid- inhibitor lastli solanezumab also
still evalu pre-symptomat ad patient amyloid plaqu show
sign dementia also patient inherit mutat caus ad due
overproduct amyloid plaqu
page
compani
page
compani therapeut focustickerev salesev ebitdapric salespric epszoeti inc anim laboratori inc anim saanim corporationfood anim anim health corporationanim health miner nutrit saanim corporationcompanion anim health vaccin privat label weight trialtrial designdata read-out expectednct idpion semaglutid semaglutid vs semaglutid vs semaglutid vs semaglutid patient moder renal outcom semaglutid flexibl dose adjust vs semaglutid insulin semaglutid monotherapi semaglutid oad combin codephas treatment regimendurationind patientsprimari completionread-out tanezumab weeksosteoarthr hip tanezumab weeksosteoarthr hip long-term safeti studytanezumab weeksosteoarthr hip tanezumab weekschron back eli lilli compani
page
rang rang rang midpointstrh estimatesconsensu gross incomenot providednot providednot incom rate wellnet incomenot providednot providednot amort intang assetsdilut share countnot providednot providednot flownot providednot providednot yellow indic chang eli lilli compani
page
millionscurrentprior chg chg total incom non-oper incom outstand analysiscurrentprior chg chg bp gross changecurrentcurr chg chg bp net product millionscurrentprior chg chg total incom non-oper incom outstand analysiscurrentprior chg chg bp gross changecurrentcurr chg chg bp net product eli lilli compani
page
compani
exhibit estim strh vs consensu
page
strh vs strh vs strh vs eli lilli compani
page
abemaciclib synjardi glyxambi insulin compani
page
 bace cgrp migrain strh- vs prior alzheim partner azn strh- growth -- -- -- differentialn/an/an/an/an/an/atot compani
exhibit incom statement
page
product incom ebita ebit non-oper incom eps-dilut excl amort post net ep outstand analysisgross percentag changenet product metricspric eli lilli compani
exhibit consolid balanc sheet
page
incom tax -- -- -- -- -- -- -- -- -- -- -- -- -- prepaid current plant equip borrow current portion lt tax current incom medic benefit non-curr paid-in benefit comprehens stock sharehold liabil sharehold eli lilli compani
exhibit statement
page
compens impair -- -- -- -- -- -- -- -- -- -- -- -- -- non-cash defer cash releas prop process common equiti -- -- -- -- -- -- -- -- -- -- -- -- -- issuanc redemp sub stock -- -- -- -- -- -- -- -- -- -- -- -- -- chang st borrow long-term long-term exchang begin end eli lilli compani
lilli lead research-bas biopharmaceut compani focus drug discoveri
clinic develop manufactur commerci pharmaceut product human
anim diseas gener sale yoy gener
us ex-u market human medicin busi includ core franchis
neurosci diabet women oncolog cardiovascular contribut
 total sale global leader diabet arena new product
trulic basaglar collabor asset jardianc tradjenta lli oncolog franchis
compris inhibitor verzenio abemaciclib alimta cyramza portrazza lartruvo
also place stake ground establish immunolog franchis
launch taltz olumi lli fourth leg emerg growth target pain market
three late-stag asset galcanezumab lasmiditan tanezumab enter one
best new product cycl year histori new product launch trulic jardianc
remain favorit growth name major biopharma year row rate buy
base attract low-teen earn growth mid-singl digit volum driven
sale growth commit expand oper margin tight cost manag
new product cycl unfold
model assum doubl diabet franchis level
jardianc basaglar trulic offset declin establish product
humalog humulin expect jardianc take materi share market older
gener therapi owe cardiovascular-benefit estim share shift
older gener therapi jardianc equat sale conting discount rebat
put upward pressur out-year estim also expect doubl
oncolog franchis base support verzenio alimta cyramza
portrazza lartruvo verzenio third-to-market inhibitor segment data
junip studi nsclc ad anoth leg growth alimta expect benefit combo use
keytruda first-lin non-smal cell lung cancer nsclc alimta alreadi substanti
presenc non-squam nsclc market model assum maintain us exclus
alimta
immunolog taltz olumi baricitinib expect contribut sale
continu progress olumi clinic commerci despit delay us
rheumatoid arthriti file think olumi long-term growth benefit expand asset
commerci reach much possibl geograph eu/japan label expans
atop dermat system lupu erythematosu psoriat arthriti taltz posit captur
mid-teen percentag psoriasi treat patient popul next five year lastli lli
emerg pain franchis repres fourth leg growth differenti late-stag asset
significantli derisk galcanezumab lasmiditan tanezumab galcanezumab robust efficaci
placebo-lik safeti posit take materi share cgrp market lasmiditan first-in-class
molecul offer cardiovascular safeti advantag acut migrain standard-
oper leverag margin expans central thesi compani contain fix
cost grow revenu base next five year lli streamlin oper
improv cost structur posit achiev opex goal sale
valuat risk
pt assum trade ep reflect premium current
forward group averag forward price-to-earnings multipl think premium group averag
multipl justifi given lli diversifi volume-driven sale growth mid-singl digit sale
compound-annual-growth-rate oper leverag oper margin goe price
target support discount cash flow dcf intrins valu per share
page
compani
risk thesi revolv around price commerci execut regulatori clinic risk
face upcom patent expir ciali alimta well recent
expir patent strattera competit pressur trulic semaglutid humalog
biosimilar insulin lispro expect off-set four launch verzenio
galcanezumab olumi baricitinib lasmiditan
compani mention note
compani buy john bori
novo nordisk nvo rate
johnson johnson rate
sanofi sni rate
novarti nv rate
zoeti inc rate
amgen inc rate
celltrion rate
astrazeneca plc azn rate
teva rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
